Study of Molecular Recognition of 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin-β-cyclodextrin Conjugate Covalently Immobilized on a Silica Surface

Synthesis under high hydrostatic pressure — a new method to prepare 5,10,15,20-tetrakis[4-(substituted amino)-2,3,5,6-tetrafluorophenyl]porphyrins

5,10,15,20-Tetrakis(pentafluorophenyl)porphyrin reacts with primary alkylamines and heterocyclic amines, at 50°C and under high pressure (450 MPa), to produce the [Formula: see text]-substituted tetraamino derivatives in high yields. Under similar conditions, the reaction with the bulky dibutylamine and dipentylamine affords the corresponding mono-substituted dialkylaminoporphyrins in 10% yield. This new protocol arises as a considerable improvement of the methods already known, which usually require high temperatures and are not effective when using secondary amines having long alkyl groups.

5,10,15,20-tetrakis(pentafluorophenyl)porphyrin: a versatile platform to novel porphyrinic materials

5,10,15,20-tetrakis(pentafluorophenyl)porphyrin reacts with a range of nucleophiles (amines, alcohols, thiols, nitrogen heterocycles, and others) resulting in the nucleophilic aromatic substitution of the para-F atoms of the pentafluorophenyl groups. This reaction, which was fortuitously discovered by Kadish and collaborators in 1990, is now being extensively used to synthesize porphyrins bearing electron-donating substituents in the para-position of their meso-aryl groups. This mini-review highlights the methods of synthesis of 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin, the use of its metal complexes in catalysis and its reaction with nucleophiles to yield new monomeric porphyrins, porphyrins supported in polymers or new polymeric porphyrin matrices useful for heterogeneous catalysis.

Porphyrin-cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy

The porphyrin-cyclodextrin conjugates were prepared and tested for selective and effective multifunctional drug delivery and therapy. The porphyrin receptor system combines efficient binding of the selected drug to the cyclodextrin cavity and photosensitizing properties of the porphyrin moiety with high accumulation of the whole complex in cancer tissue. The combined effect of chemotherapy and photodynamic therapy is demonstrated by in vitro and in vivo studies.